DXCM · Dexcom Inc
Price
Snapshot
50 fields · last close| Market Cap | $32.47B |
| P/E | 32.48 |
| Float | 375.9M |
| Beta | 1.44 |
| Volatility | 36.1% |
| Exchange | NASDAQ |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 75.4 |
| Price | 86.12 |
| Change | +0.09% |
| Prev Close | 86.04 |
| Open | 87.92 |
| Day Low | 85.80 |
| Day High | 88.87 |
| Avg Vol | 4 |
| Avg $ Vol | $302.4M |
| 52W High | 92.59 |
| 52W Low | 54.11 |
| 52W Pos | 83.2% |
| From High | −6.99% |
| From Low | +59.16% |
| Max DD 1Y | −22.83% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −0.04% |
| SMA 50 | −1.63% |
| SMA 200 | +16.47% |
| RSI (14) | 50.3 |
| Vol 30D | 29.6% |
| Vol 90D | 39.0% |
| 1Y Range | 54–93 |
| Daily bars | 537 |
| Perf Week | +2.29% |
| Perf Month | −2.15% |
| Perf Quarter | +13.67% |
| Perf Half Y | +33.15% |
| Perf Year | +29.72% |
| Perf YTD | +29.43% |
| Prev Day | +0.09% |
| Clavix | B |
| Debt / Eq | 0.00 |
| Curr Ratio | 1.88 |
| Int Cover | 32.4× |
| FCF Margin | 23.1% |
| Rev Growth | +15.6% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 29 / 49 |
What DXCM does
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Clavix risk grade
regraded every trading dayDXCM grades B, 75.4 of 100. Steadiest on Macro Resilience (65), most exposed on News Sentiment (54, mixed). 0 of the 4 weighted dimensions sit above the Health Care median. Ranks 29 of 49 in Health Care by Clavix score.
How rough the ride is
| DXCM | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.44 | 0.84 |
| Volatilityannualized | 36.1% | 20.9% |
| Max drawdown, past yearworst peak-to-trough fall | −22.8% | — |
| Typical daily movemedian absolute daily change | 1.36% | — |
| Days beyond ±3%of the last 252 sessions | 41 (16%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| DXCM | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.44 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| DXCM | |
|---|---|
| 1 week | +2.3% |
| 1 month | −2.1% |
| Year to date | +29.4% |
| 1 year | +29.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| DXCM | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 29 Aug |
| Average score0 most bearish, 100 most bullish | 63 |
| Bullish · bearisharticles above 60 · below 40 | 20 · 4 |
| Directionarticles whose tone is improving vs worsening | 20 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| DXCM | |
|---|---|
| Revenue growthyear over year | +15.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openDexCom's switch to a 15-day continuous glucose monitor sensor cut manufacturing costs enough to lift its gross profit margin about four percentage points in the latest quarter, as newly published study results in a top medical journal support expanding use to people with Type 2 diabetes who don't take insulin.
Users of the Dexcom continuous glucose monitor app reported that a recent update blocked blood sugar readings behind a new terms of use and privacy policy, requiring immediate agreement to continue using the app. Critics, including a privacy researcher, called the consent screen coercive, and users flagged provisions they said allow tracking of mobile device data including browsing history and require disputes to go to arbitration instead of court. Dexcom issued statements on social media and via email in response, though the article text was cut off before the company response was fully captured.
Dexcom's CONNECT trial, published in The New England Journal of Medicine, showed that Type 2 diabetes patients not on insulin who used the Dexcom G7 continuous glucose monitor (CGM) lowered their A1C (a measure of average blood sugar over months) by 0.9 percentage points more than those on routine care, spent about five more hours per day in healthy blood sugar range, and 97% were still using the device at 26 weeks.
Dexcom announced that results from its CONNECT randomized controlled trial were published in The New England Journal of Medicine, showing that adults with Type 2 diabetes who do not use insulin reduced their A1C, a blood test measuring average blood sugar over about three months, by an average of 1.6 percentage points (from a starting level of 8.8% down to 7.2%) while using the Dexcom G7 continuous glucose monitor.
Dexcom announced that results from its CONNECT randomized controlled trial were published in The New England Journal of Medicine, showing that adults with Type 2 diabetes not on insulin who used Dexcom G7 continuous glucose monitors (CGM) achieved an average 1.6% reduction in A1C (a standard blood sugar measure) from a baseline of 8.8%.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| GEHC | GE Healthcare Technologies Inc | B | $31.42B | 15.83 | 0.83 | Compare |
| RMD | Resmed Inc | B+ | $33.61B | 22.06 | 0.77 | Compare |
| CNC | Centene Corp | B | $34.16B | — | 1.08 | Compare |
| ALC | Alcon AG | B+ | $27.54B | 40.81 | 1.07 | Compare |
| DGX | Quest Diagnostics Inc | A- | $25.94B | 24.42 | 0.56 | Compare |
| LH | Labcorp Holdings Inc | A- | $25.79B | 25.73 | 0.89 | Compare |
| IDXX | IDEXX Laboratories Inc | B+ | $44.15B | 38.74 | 1.55 | Compare |
| MDLN | Medline Inc | B | $47.28B | 68.22 | 0.95 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.